

1 PATIENT INFORMATION Patient Name: _____ Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ MRN #: _____ DOB: _____ Drug Allergies: _____	2 PRESCRIBER INFORMATION Prescriber's Name: _____ DEA#: _____ NPI: _____ Clinic/Facility Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____
---	--

3 CLINICAL INFORMATION
 Diagnosis (ICD-10 code): _____
 Previous Alpha-1 Therapy: Aralast NP Prolastin-C Powder Prolastin-C Liquid Zemaira Other: _____
 Last Dose: _____ grams or _____ mg/kg Date of Last Dose: _____
 Frequency of infusion: _____

4 ALPHA-1 PROTEINASE INHIBITOR PRESCRIPTION INFORMATION

 First Dose: No Yes Weight: _____ kg Date Recorded: _____
 Alpha-1 Proteinase Inhibitor Product: Aralast NP (preferred) Prolastin-C Powder Route: Intravenous
 Dose in mg/kg: _____ +/- 10% + 20% / -10% Other: _____
 Frequency: _____
 Refills: 11 months Other _____
 Infusion Access: PIV CVAD Other: _____
 Patient's Current Home Care/Specialty Pharmacy: _____

Infusion Reaction Medications & Supplies

<input checked="" type="checkbox"/> Hydrocortisone sodium succinate injectable 100 mg IV Sig: Once PRN for hypersensitivity <input checked="" type="checkbox"/> Epinephrine Auto-Injector <input type="checkbox"/> 0.15mg <input type="checkbox"/> 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use. <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV Flush : Flush 10 ml IV before/after medication administration or as needed for line maintenance	<input checked="" type="checkbox"/> Diphenhydramine injectable 25 mg IV Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath <input checked="" type="checkbox"/> Sodium Chloride 0.9% IV 250ml Bag Sig: Once PRN for anaphylaxis
---	--

 Labs /Special Instructions/Pre-Meds: _____

Alpha-1 Proteinase Inhibitor Infusion Protocol: <ul style="list-style-type: none"> • Infuse per manufacturer guidelines • Monitor vital signs (Temp, BP, HR, RR) every 15 minutes x 4; then every 30 minutes x2; then every 60 minutes until completion of infusion • First Infusion: Do <u>not</u> exceed an infusion rate of <ul style="list-style-type: none"> ○ Aralast NP = 0.2 mL/kg/min ○ Prolastin-C = 0.08 mL/kg/min • Documentation must include: <ul style="list-style-type: none"> ○ Start and end time of infusion ○ All rate changes, vital signs, including initial and final set ○ Patient response 	<ul style="list-style-type: none"> • Observe patient for signs of infusion rate-related adverse reactions: <ul style="list-style-type: none"> ○ Blood pressure changes, increased pulse rate ○ Fever, chills ○ Headache ○ Chest, back or hip pain ○ Dyspnea ○ Mild erythema
---	---

5 PHYSICIAN SIGNATURE REQUIRED	
X _____ SUBSTITUTION PERMITTED (Date)	X _____ DISPENSE AS WRITTEN (Date)

CONFIDENTIALITY NOTICE: This message and any attached files might contain confidential information protected by federal and state law. The information is intended only for the use of the individual(s) or entities originally named as addressees. The improper disclosure of such information may be subject to civil or criminal penalties. If this message reached you in error, please contact the sender and destroy this message. Disclosing, copying, forwarding, or distributing the information by unauthorized individuals or entities is strictly prohibited by law.

Members with Medicare Part B or D coverage are not required to use this form.